Search "HBOT and cancer" and you'll hit two walls of noise. One side claims hyperbaric oxygen "starves" or "kills" cancer by flooding tumors with oxygen. The other warns it "feeds" cancer because oxygen fuels cell growth. Both are oversimplified, and the second one was the dominant fear in oncology for decades. The honest answer from the published research sits in between: hyperbaric oxygen therapy (HBOT) does not reliably kill cancer cells as a standalone treatment in humans, but it also does not appear to make cancer grow or spread, and its one genuinely evidence-backed role in cancer care is repairing radiation damage in survivors.
This article walks through the actual biology, separates lab-dish findings from human outcomes, grades the evidence honestly, and flags exactly where the marketing outruns the data.
What HBOT actually does to oxygen levels
HBOT means breathing close to 100% oxygen inside a sealed chamber pressurized above sea level, usually between 2.0 and 2.5 times normal atmospheric pressure (ATA). At those pressures, far more oxygen dissolves directly into blood plasma instead of riding only on hemoglobin. Tissue oxygen levels can climb many times higher than normal during a session.
The cancer relevance starts with a concept called tumor hypoxia. Solid tumors grow faster than their blood supply can keep up with, so the inside of many tumors becomes starved of oxygen. That low-oxygen core is not a weakness for the cancer. It is one of its advantages.
If you want the broader physiology first, see how HBOT increases tissue oxygenation and the full complete science guide.
One detail trips up a lot of the marketing. A normal HBOT session is intermittent, not constant. Patients breathe high-pressure oxygen for 60 to 90 minutes, then return to normal air for the rest of the day. The body sees a spike, not a permanent flood. That matters because some of the proposed anti-cancer effects depend on the swing between high and normal oxygen, a pattern that can stress cells and trigger reactive oxygen species, rather than on simply soaking tissue in oxygen forever. It is a more subtle picture than "more oxygen = dead tumor."
Why tumor hypoxia matters
Hypoxic tumor regions are the aggressive ones. Cancer cells in low oxygen switch on a master regulator called HIF-1alpha (hypoxia-inducible factor 1-alpha). HIF-1alpha turns on genes that help the tumor survive without oxygen, build new blood vessels, resist cell death, and become harder to kill with radiation and some chemotherapy drugs.
This is the root of the "oxygen feeds cancer" myth. The myth borrows from the Warburg effect, the 1920s observation that cancer cells rely heavily on glucose fermentation even when oxygen is available. People hear "cancer and oxygen are linked" and assume more oxygen equals more cancer. The biology actually points the other way for a lot of tumors. Hypoxia, not oxygen, drives the most dangerous behaviors. Reoxygenating a tumor can, in lab models, blunt the HIF-1alpha program rather than feed it.
The mechanism case for HBOT against cancer
In cell and animal studies, raising tumor oxygen has produced several anti-cancer effects:
- Lowered HIF-1alpha and reduced expression of its downstream survival genes
- Reversal of the Warburg metabolism in some hypoxic lung cancer cell lines, shifting cells away from the aggressive glycolytic state
- Induced apoptosis (programmed cell death) in certain transferred tumor cells
- Radiosensitization, because radiation needs oxygen to generate the DNA-damaging free radicals that kill cells; a well-oxygenated tumor is up to roughly three times more radiation-sensitive than a hypoxic one
That last point is the most clinically important and the least hyped. Oxygen is one of the oldest known radiosensitizers in radiation oncology.
Why none of that proves it kills cancer in you
Read those bullets carefully and you'll notice the honest gap. Each effect is a step a cancer-killing process might use, not the finished result. Lowering HIF-1alpha could make a tumor less aggressive. Reversing Warburg metabolism could slow a cell line in a dish. Inducing apoptosis in cultured cells is a long way from shrinking a tumor inside a living person whose immune system, blood supply, and other organs all complicate the picture.
Cell cultures lack a real blood supply, a real immune system, and the messy three-dimensional structure of a human tumor. Mouse tumors are usually implanted, fast-growing, and genetically uniform in ways human cancers are not. Treatments that look spectacular in those settings fail in human trials all the time. This is one of the most reliable patterns in cancer research, and it's exactly why "it killed cancer cells in a study" is a near-meaningless phrase without specifying which study and in what.
Lab dish vs living human: the gap that matters
Here is where hype collides with reality. Almost all the "HBOT kills cancer" findings come from cell cultures and mouse models. Those are useful for understanding mechanism. They are weak predictors of what happens in patients.
The table below separates what is shown where.
| Claim | Evidence type | What it actually shows | Strength |
|---|---|---|---|
| HBOT lowers HIF-1alpha in tumor cells | Cell line + some animal | Real, reproducible in specific cancers (e.g., NSCLC) | Moderate (preclinical) |
| HBOT induces tumor cell apoptosis | Cell line + animal (e.g., A549 lung) | Seen in select models, not all | Weak-moderate (preclinical) |
| HBOT shrinks tumors in humans alone | Human | No reliable evidence as monotherapy | Very weak / none |
| HBOT makes radiation work better | Human + preclinical | Plausible mechanism; small/older human trials suggestive, not definitive | Weak-moderate |
| HBOT causes cancer to grow or spread | Human + preclinical | No good evidence it promotes growth, recurrence, or metastasis | Reassuring (safety) |
| HBOT heals radiation injury in survivors | Human (incl. RCTs) | Strongest, real-world clinical use | Moderate (best in this list) |
The single biggest takeaway: no published human trial shows HBOT alone killing cancer or curing a tumor. Anyone selling it that way is ahead of the science.
What the research looks like by cancer type
The preclinical signal is not uniform. It varies a lot depending on the cancer, which is another reason blanket claims fall apart. Here's a rough map of where studies have looked and what they suggest. Remember: nearly all of this is cell-dish or animal work, so read it as "direction of a hypothesis," not "what happens to patients."
| Cancer type | Main study setting | Reported preclinical direction | Human evidence? |
|---|---|---|---|
| Lung (NSCLC, A549) | Cell line + mouse | Reduced HIF-1alpha, reversed Warburg, apoptosis | None for cure |
| Breast | Animal xenograft | Less aggressive growth in some hyperoxia models | None for cure |
| Colorectal | Cell + animal | Mixed; some suppression signals | None for cure |
| High-grade glioma (brain) | Small human + preclinical | Possible radiosensitizing benefit when paired with radiation | Old, small trials only |
| Neuroblastoma | Narrative/preclinical | Proposed adjunct effects | None |
The pattern is consistent: interesting laboratory hints, no confirmed human anti-tumor cure. Even the studies most often cited by HBOT-for-cancer marketers, like the A549 lung cancer work showing tumor suppression and apoptosis, are animal-model results that the authors themselves frame as needing clinical confirmation.
The "does it feed cancer" question, answered honestly
For decades oncologists worried that the wound-healing effects of HBOT, which include stimulating new blood vessel growth, might also feed tumors or trigger recurrence. That caution made sense. It just has not held up under review.
Two systematic reviews concluded that HBOT in patients with cancer is considered safe and found no evidence that it acts as a tumor promoter or recurrence enhancer. A 2025 safety evaluation of cancer patients who received HBOT, mostly for treatment complications, found no significant correlation between the number of HBOT sessions and either metastasis or mortality. Some studies even point the other way, toward less aggressive tumor behavior after hyperoxia.
That said, two caveats keep this honest. First, "no evidence of harm" is not the same as "proven safe for every cancer type," because the studied populations are limited and cancers vary enormously. Second, the data are not robust enough to rule out a small effect in a specific tumor type. The reasonable reading: HBOT is not a known cancer accelerant, but active cancer is still treated as a relative contraindication for elective wellness use until you have an oncologist's sign-off.
Where HBOT genuinely earns its place in cancer care
Strip away the "kills cancer" hype and there is a real, established cancer-adjacent use: fixing the collateral damage radiation leaves behind.
Radiation that destroys a tumor also scars nearby healthy tissue. Months or years later, that tissue can break down because its blood supply is wrecked. This is late radiation tissue injury (LRTI), and it shows up as jaw bone death (osteoradionecrosis), bladder bleeding (radiation cystitis), and bowel injury (radiation proctitis). HBOT stimulates new blood vessels and helps this oxygen-starved scar tissue heal.
| Cancer-related use of HBOT | Goal | Evidence quality | Status |
|---|---|---|---|
| Late radiation tissue injury (osteoradionecrosis, cystitis, proctitis) | Heal damaged healthy tissue | Best evidence; includes RCT data | UHMS-approved indication |
| Radiosensitizer before/with radiotherapy | Make tumors easier to kill with radiation | Older, small human trials; mostly preclinical | Investigational |
| Adjunct to chemo / immunotherapy | Improve drug delivery, ease hypoxia-driven resistance | Mostly preclinical | Investigational |
| Standalone tumor treatment | Kill the cancer directly | No reliable human evidence | Not supported |
The strongest single piece of human evidence here is the RICH-ART trial, a randomized, controlled phase 2-3 study run at five Nordic university hospitals. It enrolled adults who'd had pelvic radiotherapy at least six months earlier and developed radiation cystitis, then randomly assigned them to HBOT (30 to 40 sessions at roughly 2.4 ATA) or standard care. The HBOT group reported relief of bladder symptoms, and the treatment was safe and well tolerated. That's a properly designed human trial showing benefit, which is exactly what's missing from every "HBOT kills cancer" claim.
Backing it up, a 2023 Cochrane systematic review of HBOT for late radiation tissue injury pulled together 18 studies and over 1,000 participants. It found HBOT may produce complete resolution or significant improvement of certain late radiation injuries, especially jaw osteoradionecrosis and radiation cystitis and proctitis, while honestly noting the evidence base still has gaps and not every site or patient benefits. For more on this, see HBOT for radiation tissue damage and the late radiation tissue injury evidence atlas.
So the cleanest summary of HBOT's real cancer role: it does not kill the cancer, it repairs what curing the cancer damaged.
The immunotherapy and microenvironment angle
A newer research thread is more interesting than the old "kill the tumor with oxygen" pitch, and it's worth understanding because it's where serious labs are actually looking. Hypoxia inside a tumor doesn't just make cancer cells tougher. It also suppresses the immune cells that should be attacking the tumor and weakens the delivery of drugs. The idea is that reoxygenating the tumor microenvironment could make the cancer more vulnerable to treatments that are already proven, rather than acting as a treatment by itself.
In preclinical work, raising tumor oxygen has been linked to:
- Better drug penetration into dense, poorly perfused tumor tissue
- Eased immunosuppression, potentially helping immune checkpoint drugs work
- Reduced cancer stem cell survival, the cells thought to drive recurrence
- More DNA damage from radiation, the radiosensitizing effect again
This is genuinely promising mechanistically. It is also almost entirely preclinical. There is no established protocol where HBOT is added to immunotherapy in routine care, and the human trials needed to prove it helps simply have not been done at scale yet. So file it under "active research," not "available treatment." If a clinic claims HBOT supercharges your immunotherapy, the honest response is that the science isn't there yet.
The radiosensitizer angle: promising but unproven
The most scientifically interesting "treat the cancer" idea is using HBOT to oxygenate a tumor right before radiation, making the radiation hit harder. Small and mostly older human trials, including phase 2 work in high-grade brain tumors (gliomas), reported reasonable tumor responses and acceptable safety when radiation followed immediately after a hyperbaric session.
Why isn't this standard? Logistics and evidence. Delivering radiation within minutes of decompression is operationally hard, and the trials are small, old, and rarely randomized with modern controls. Newer radiosensitizing drugs and techniques competed it out of routine practice. It remains a real research direction, not a proven therapy you can book today.
How HBOT compares to other "oxygen" and metabolic cancer claims
HBOT gets lumped in with a whole family of alternative cancer ideas built around oxygen and metabolism. It's worth drawing lines between them, because they are not equally supported and HBOT is actually the most legitimate of the bunch in its narrow, real role.
| Approach | Core claim | Evidence in humans | Honest verdict |
|---|---|---|---|
| HBOT for radiation injury | Heals radiation-damaged tissue | RCT + systematic review | Real, approved use |
| HBOT as standalone cancer cure | Oxygen kills the tumor | None | Not supported |
| Ozone therapy | "Oxygenates" and kills cancer | No credible cancer evidence | Not supported, can be harmful |
| Hydrogen peroxide / "oxygen" supplements | Flood body with oxygen | No credible evidence | Not supported, dangerous |
| Ketogenic metabolic therapy | Starve cancer's glucose | Early research, unproven as cure | Investigational |
The pattern: HBOT's credibility comes entirely from its repair-and-radiosensitizer biology and its one approved survivorship use. It is not in the same category as ozone or hydrogen peroxide schemes, which have no legitimate cancer evidence and real toxicity. Don't let HBOT's modest, real role be used to launder claims about the unproven cousins. If you're comparing wellness modalities generally, the HBOT vs red light therapy breakdown and the alternatives guide cover non-cancer use cases.
Reading the evidence grade honestly
If you only remember one framework, use this:
- Strong-ish (for an HBOT topic): healing late radiation injury in cancer survivors. Real human trials, an approved indication, plausible mechanism.
- Weak / preliminary: HBOT as a radiosensitizer or chemo/immunotherapy adjunct. Good mechanism, thin human data.
- Unsupported hype: HBOT alone killing tumors, "starving" cancer of nothing, curing cancer, replacing oncology care.
A lot of the splashy "HBOT fights cancer" content cites cell-dish and mouse studies as if they were human results. Some of it traces back to clinics or device sellers with a financial stake. Treat any clinic that markets HBOT as a cancer treatment, rather than a complication-management tool, as a red flag. The myth-debunking companion piece, HBOT myths debunked, covers more of these claims.
Safety considerations if you have or had cancer
HBOT is generally well tolerated, but it carries its own risks independent of cancer: ear and sinus barotrauma from pressure changes, temporary nearsightedness, claustrophobia, and rare oxygen-toxicity seizures. For active cancer specifically, the practical guidance is conservative:
- Active, untreated cancer is treated as a relative contraindication for elective or wellness HBOT until an oncologist clears it.
- HBOT for radiation injury is typically done in cancer survivors after treatment, coordinated with their oncology team.
- It should never replace or delay standard cancer treatment.
- It does not substitute for surgery, chemotherapy, radiation, or immunotherapy.
For a full risk rundown, see HBOT side effects and risks and contraindications.
Who this is actually for
HBOT for a cancer-related reason makes sense in a narrow group:
- Cancer survivors with confirmed late radiation injury (jaw, bladder, bowel) who haven't responded to first-line care
- Patients facing certain head-and-neck dental or surgical procedures in previously irradiated tissue, to lower the risk of bone breakdown
It does not make sense as a do-it-yourself cancer treatment, a tumor "cure," or a reason to skip oncology. If a chamber is being sold to you as cancer therapy, ask for the human trial data. There isn't any that supports it as a tumor-killer.
Frequently Asked Questions
Can HBOT cure cancer on its own?
No. There is no reliable human evidence that hyperbaric oxygen alone kills tumors or cures cancer. The lab findings about reduced HIF-1alpha and induced cell death come from cell cultures and animal models, which do not translate directly to patients. Its proven cancer-related use is healing radiation damage, not destroying the cancer.
Does HBOT make cancer grow or spread?
Available human and review evidence does not show HBOT promoting tumor growth, recurrence, or metastasis, and two systematic reviews judged it safe in cancer patients. This contradicts the old "oxygen feeds cancer" fear. The data aren't unlimited, though, so active cancer is usually cleared with an oncologist before any elective HBOT.
What is the strongest evidence-backed cancer use of HBOT?
Treating late radiation tissue injury in cancer survivors, such as radiation cystitis, proctitis, and osteoradionecrosis of the jaw. This is a recognized indication supported by randomized trial data and a Cochrane systematic review, and it targets the healthy tissue damaged by radiation rather than the tumor itself.
Doesn't the Warburg effect mean oxygen feeds cancer?
The Warburg effect describes how cancer cells rely on glucose fermentation, but it doesn't mean extra oxygen feeds tumors. The most aggressive cancer behavior is actually driven by low oxygen (hypoxia) and HIF-1alpha. In several lab models, reoxygenating tumors blunted that aggressive program rather than fueling it.
Should I use HBOT instead of chemotherapy or radiation?
No. HBOT is not a substitute for standard cancer treatment and should never replace or delay surgery, chemotherapy, radiation, or immunotherapy. Its only mainstream cancer role is supportive, usually after treatment, to repair radiation injury, and it should always be coordinated with your oncology team.
Medical disclaimer: This article is for general information only and is not medical advice. Talk to a qualified oncologist or physician before considering hyperbaric oxygen therapy for any cancer-related reason.
Sources
- Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer — a review. Target Oncol, 2012 (PMID 23054400)
- Hyperbaric Oxygen Therapy for Managing Cancer Treatment Complications: A Safety Evaluation. Medicina, 2025 (PMID 40142196)
- Hyperbaric Oxygen Therapy for Managing Cancer Treatment Complications: A Safety Evaluation — full text (PMC11943617)
- Lin ZC, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev, 2023 (PMID 37585677)
- Oscarsson N, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol, 2019 (PMID 31537473)
- Hyperbaric oxygen suppressed tumor progression through improvement of tumor hypoxia and induction of apoptosis in A549 lung cancer. Sci Rep, 2021
- Hyperbaric Oxygen Therapy Represses the Warburg Effect and EMT in Hypoxic NSCLC Cells via the HIF-1α/PFKP Axis. Front Oncol, 2021
- PubMed: hyperbaric oxygen therapy, cancer, and tumor growth (search)
- PubMed: hyperbaric oxygen with radiotherapy for high-grade glioma (search)